A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder

Trial Profile

A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs KP-415 (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors KemPharm
  • Most Recent Events

    • 22 Sep 2017 Status changed from planning to not yet recruiting.
    • 06 Jul 2017 New trial record
    • 28 Jun 2017 According to a KemPharm media release, this trial is planned to initiate in the second half of 2017 and in alignment with an NDA submission in late 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top